



Psoriasis in adults: LSCMMG Biologic and High Cost Drug Commissioning Pathway

David Prayle

Midlands and Lancashire CSU

Version 1.9 November 2025

Review date: November 2028

Version Number	Amendments made	Author	Date
1.0		David Prayle	12 April 2016
1.1		David Prayle	3 August 2016
1.2	Post LMMG minor accuracy changes made	David Prayle	14 September 2016
1.3	Addition of Ixekizumab	David Prayle	March 2018
1.4	Addition of brodalumab and nonbiologic high cost drugs, title updated to include reference to nonbiologic drugs	David Prayle	May 2018
1.5	Addition of guselkumab	David Prayle	November 2018
1.6	Addition of tildrakizumab and risakizumab	Sharon Andrew, David Prayle	September 2019
1.7	Lines of biologic increased to six options. Position of Apremilast and dimethyl fumarate clarified.	David Prayle	July 2020
1.8	Addition of bimekizumab. Edits to improve flow of text.	Jill Gray	November 2022
1.9	Addition of deucravacitinib, addition of small molecules to flowchart. Removal of background information.	Sharon Andrew, David Prayle	November 2025
Date of next review: November 2028			

Psoriasis: LSCMMG High-Cost Drugs Commissioning Pathway

